Global Revenue Of Animal Stem Cell Therapy Is Nearly 16.3 M USD In 2017
Wednesday, 24 Oct, 2018
Animal stem cell therapy is a usage of animal’s stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease.
In the last several years, global market of Animal Stem Cell Therapy developed rapidly, with an average growth rate of 36.03%. In 2017, global revenue of Animal Stem Cell Therapy is nearly 16.3 M USD.
The classification of animal stem cell therapy includes dogs, horses and others. And the proportion of dogs in 2017 is about 50.42%, and the proportion is in increasing trend from 2013 to 2017.
Animal Stem Cell Therapy is widely used in veterinary hospitals and research organizations. The most proportion of Animal Stem Cell Therapy is used in veterinary hospitals, and the revenue in 2017 is 13 M USD.
North America is the largest consumption region of animal stem cell therapy, with a consumption market share nearly 58.63% in 2017. Japan is the second largest supplier of animal stem cell therapy, enjoying production market share nearly 15.17% in 2017.
Market competition is intense. Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.